PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC

被引：0
|
作者：
Marzia Del Re
Riccardo Marconcini
Giulia Pasquini
Eleonora Rofi
Caterina Vivaldi
Francesco Bloise
Giuliana Restante
Elena Arrigoni
Chiara Caparello
Maria Grazia Bianco
Stefania Crucitta
Iacopo Petrini
Enrico Vasile
Alfredo Falcone
Romano Danesi
机构：
[1] Clinical Pharmacology and Pharmacogenetics Unit,Department of Clinical and Experimental Medicine
[2] University of Pisa,Department of Translational Research and New Technologies in Medicine and Surgery
[3] Medical Oncology Unit,Department of Translational Research and New Technologies in Surgery and Medicine
[4] University of Pisa,undefined
[5] General pathology,undefined
[6] University of Pisa,undefined
来源：
British Journal of Cancer | 2018年 / 118卷
关键词：
PD-L1; exosomes; circulating nucleic acids; immunotherapy; predictive biomarker; pharmacogenetics; nivolumab; pembrolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：820 / 824
页数：4
相关论文
共 50 条
  • [31] Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy
    Garcia-Aranda, Marilina
    Redondo, Maximino
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (09)
  • [32] Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis
    Yang, Yuanyuan
    Wang, Feng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [33] Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
    Bie, Fenglong
    Tian, He
    Sun, Nan
    Zang, Ruochuan
    Zhang, Moyan
    Song, Peng
    Liu, Lei
    Peng, Yue
    Bai, Guangyu
    Zhou, Bolun
    Gao, Shugeng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [34] Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy
    Valecha, Gautam Kishore
    Vennepureddy, Adarsh
    Ibrahim, Uroosa
    Safa, Firas
    Samra, Bachar
    Atallah, Jean Paul
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (01) : 47 - 59
  • [35] Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
    Bevins, Nicholas J.
    Okamura, Ryosuke
    Montesion, Meagan
    Adashek, Jacob J.
    Goodman, Aaron M.
    Kurzrock, Razelle
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2022, 5 (04) : 90 - 97
  • [36] The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer
    Ito, Kentaro
    Miura, Satoru
    Sakaguchi, Tadashi
    Murotani, Kenta
    Horita, Nobuyuki
    Akamatsu, Hiroaki
    Uemura, Kohei
    Morita, Satoshi
    Yamamoto, Nobuyuki
    LUNG CANCER, 2019, 128 : 113 - 119
  • [37] Impact of Renin-angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients
    Tozuka, Takehiro
    Yanagitani, Noriko
    Yoshida, Hiroshi
    Manabe, Ryo
    Ogusu, Shinsuke
    Tsugitomi, Ryosuke
    Sakamoto, Hiroaki
    Amino, Yoshiaki
    Ariyasu, Ryo
    Uchibori, Ken
    Kitazono, Satoru
    Seike, Masahiro
    Gemma, Akihiko
    Nishio, Makoto
    ANTICANCER RESEARCH, 2021, 41 (04) : 2093 - 2100
  • [38] The predictive value of PD-L1 expression in response to anti-PD-1/PD-L1 therapy for biliary tract cancer: a systematic review and meta-analysis
    Yoon, Seung Bae
    Woo, Sang Myung
    Chun, Jung Won
    Kim, Dong Uk
    Kim, Jaihwan
    Park, Joo Kyung
    So, Hoonsub
    Chung, Moon Jae
    Cho, In Rae
    Heo, Jun
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [39] PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival
    Micevic, Goran
    Thakral, Durga
    McGeary, Meaghan
    Bosenberg, Marcus W.
    PIGMENT CELL & MELANOMA RESEARCH, 2019, 32 (03) : 435 - 440
  • [40] Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer
    Wang, Luyao
    Ma, Qingxia
    Yao, Ruixue
    Liu, Jia
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 79
12345